Experienced in Thrombocytopenia

Dr. Frederic J. Kaye

Hematology Oncology | Oncology
1600 Sw Archer Rd, 
Gainesville, FL 
Accepting New Patients
Experienced in Thrombocytopenia
1600 Sw Archer Rd, 
Gainesville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Frederic Kaye is a Hematologist Oncology specialist and an Oncologist in Gainesville, Florida. Dr. Kaye is rated as an Experienced provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Lung Adenocarcinoma, and Squamous Cell Lung Carcinoma. Dr. Kaye is currently accepting new patients.

His clinical research consists of co-authoring 58 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Thrombocytopenia.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

1600 Sw Archer Rd, Gainesville, FL 32610

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
Feasibility, Acceptability, and Efficacy of a Yoga Intervention for Distress in Women With Gynecologic, Gastrointestinal, or Thoracic Cancer
Feasibility, Acceptability, and Efficacy of a Yoga Intervention for Distress in Women With Gynecologic, Gastrointestinal, or Thoracic Cancer
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: June 02, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 3
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

58 Total Publications

Integrated proteomic analysis identifies TYMS-dependent AMPK-mTOR signaling in pancreatic neuroendocrine tumors.
Integrated proteomic analysis identifies TYMS-dependent AMPK-mTOR signaling in pancreatic neuroendocrine tumors.
Journal: iScience
Published: February 07, 2025
Similar Doctors
Distinguished in Thrombocytopenia
Dr. Daniel A. Patterson
Hematology Oncology | Hematology | Oncology
Distinguished in Thrombocytopenia
Dr. Daniel A. Patterson
Hematology Oncology | Hematology | Oncology
3256 S Pine Ave, Suite 303, 
Ocala, FL 
 (35.9 miles away)
352-512-0688
Experience:
44+ years
Languages Spoken:
English, Russian, Spanish
See accepted insurances
Accepting New Patients

Daniel Patterson is a Hematologist Oncology specialist and a Hematologist in Ocala, Florida. Dr. Patterson has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Anemia, Lymphoid Hyperplasia, Thrombocytopenia, Childhood Iron Deficiency Anemia, and Bone Marrow Aspiration. Dr. Patterson is currently accepting new patients.

Distinguished in Thrombocytopenia
Dr. Andrew M. Weber
Hematology | Hematology Oncology | Oncology
Distinguished in Thrombocytopenia
Dr. Andrew M. Weber
Hematology | Hematology Oncology | Oncology

Ocala Oncology Center Pl

3130 Sw 32nd Ave, 
Ocala, FL 
 (34.9 miles away)
352-732-4032
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Weber is a Hematologist and a Hematologist Oncology provider in Ocala, Florida. Dr. Weber is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Febrile Neutropenia. Dr. Weber is currently accepting new patients.

Distinguished in Thrombocytopenia
Dr. Vernon Montoya
Oncology | Hematology | Hematology Oncology
Distinguished in Thrombocytopenia
Dr. Vernon Montoya
Oncology | Hematology | Hematology Oncology

Lake City Cancer Care LLC

289 Sw Stonegate Ter, Suite 103, 
Lake City, FL 
 (43.3 miles away)
386-755-1655
Languages Spoken:
English
See accepted insurances

Vernon Montoya is an Oncologist and a Hematologist in Lake City, Florida. Dr. Montoya is rated as a Distinguished provider by MediFind in the treatment of Thrombocytopenia. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Acute Mountain Sickness, and Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kaye's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile